Intervention | N. of participants (N. of arms, control) | Dose, period (weeks) | Primary measurement (subscale) | Statistical significance |
---|---|---|---|---|
Psychiatric drugs | ||||
 (-)-OSU6162 [16] | 62 (2, placebo) | 30 mg, 60 mg/day, 2 | MFS, CGI | Not significant |
 Duloxetine [17] | 60 (2, placebo) | 60–120 mg/day, 12 | MFI (general fatigue) | Not significant |
 Clonidine-hydrochloride [18] | 188 (3, placebo, HC) | 50 μg or 100 μg/day, 9 | Number of steps per day | Not significant |
 Methylphenidate [19] | 60 (crossover, placebo) | 10 mg/day, 4 | CIS (fatigue, concentration) VAS (fatigue, concentration) | CIS (fatigue): P < 0.01, VAS: P < 0.01 |
 Galantamine hydrobromide [20] | 434 (5, placebo) | 7.5–30 mg/day, 16 | CGI | Not significant |
 Moclobemide [21] | 90 (2, placebo) | 450–600 mg/day, 6 | Globally improved cases, KPS, POMS | Not significant |
 Fluoxetine [22] | 96 (2, placebo) | 20 mg/day, 8 | CIS (fatigue)a | Not significant |
 Galantamine hydrobromide [23] | 49 (2, placebo) | 30 mg/day, 8 | VAS (fatigue) | Not significant |
Immunomodulators | ||||
 BioBran MGN-3 [24] | 71 (2, placebo) | 6 g/day, 8 | Chalder scale(physical) | Not significant |
 Staphypan Berna [25] | 100 (2, placebo) | 0.1–1.0 ml/week and 1.0 ml/4 weeks, 24 | CGI, CPRS | CGI: P < 0.001, CPRS: P < 0.01 |
 Gamma globulin [26] | 71 (2, placebo) | 1 gm/kg 3 times/month, 8 | Mean functional score | P < 0.05 (6 month) |
 Poly(I):poly(C12U) [27] | 92 (2, placebo) | 400–800 mg/week, 24 | KPSa | P < 0.05 |
Cortisol | ||||
 Hydrocortisone + 9-alfa-fludrocortisone [28] | 80 (crossover, placebo) | 5 mg + 50 μg/day, 12 | VAS (fatigue) | Not significant |
 Fludrocortisone acetate [29] | 100 (2, placebo) | 0.1 mg/day, 9 | Global wellness score | Not significant |
 Hydrocortisone [30] | 32 (crossover, placebo) | 5 or 10 mg/day, 4 | Chalder scale, CGI | Chalder scale: P < 0.01 |
 Hydrocortisone [31] | 70 (2, placebo) | 16 mg/m2/day, 12 | Global wellness score | Not significant |
 Fludrocortisone acetate [32] | 25 (crossover, placebo) | 0.1–0.2 mg/day, 6 | VAS, SF-36a | Not significant |
Mitochondrial modulators | ||||
 KPAX002 [33] | 128 (2, placebo) | 12 mg/day, 12 | CIS (total score) | Not significant |
 CoQ10 + NADH [34] | 73 (2, placebo) | 200 mg + 20 mg/day, 8 | FIS-40 (total score) | P < 0.05 |
 NADH [35] | 26 (crossover, placebo) | 10 mg/day, 4 | Self-developed subject symptom scoring system | Not significant |
Nutrients | ||||
 Acclydine [36] | 57 (2, placebo) | 1000–125 mg/day, 14 | CIS (fatigue), SIP-8 | Not significant |
 Polynutrient supplement [37] | 63 (2, placebo) | 125 ml/day, 10 | CIS (fatigue), N of CDC symptoms, SIP-8 | Not significant |
Others | ||||
 Anakinra [38] | 50 (2, placebo) | 100 mg/day, 4 | CIS (fatigue) | Not significant |
 Ondansetron [39] | 67 (2, placebo) | 16 mg/day, 10 | CIS (fatigue), SIP-8 | Not significant |
 Homeopathic treatment [40] | 103 (2, placebo) | Not fixed, 24 | MFI | Not significant |